|CLSN's rally has carried over into Monday morning:|
Celsion Corporation (NASDAQ: CLSN) also made an enormous recovery too, moving up an incredible 45% in the last five trading sessions and roughly 20% throughout last week. CLSN is now 22.4% higher than it was after initial coverage by Bio-Wire on October 1st, 2012 which claimed that the stock was generating bullish potential based on the upcoming phase III clinical trial results of the HEAT study - the study that will provide results that will be used in the eventual NDA for Celsion's flagship product ThermoDox for the treatment of liver cancer.
Since liver cancer is one of the most challenging types of cancer to treat, and since unmet demand is already enormous (and growing) for this particularly disease, ThermoDox has very exciting prospects given that it can provide a favorable efficacy and safety profile when we see the data in December 2012. A recent article on Option Monster also caught my attention, since it alerted me to some really serious buying in call options that are set to expire in January and February. There is clearly some interest in CLSN stock, anticipating the upcoming clinical trial data for ThermoDox. Momentum traders should consider CLSN since it seems that there is strong bias on the bullish side as we wait - particularly in the options market.